The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Self-citationNavari, R. M., Gray, S. E., & Kerr, A. C. (2011) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2011.05.002 · Cited by 319
Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M. E., Bondarenko, I., Sarosiek, T., Oprean, C., Cardona-Huerta, S., Lorusso, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu101 · Cited by 250
Self-citationRapoport, B. L., Jordan, K., Boice, J. A., Taylor, A., Brown, C., Hardwick, J. S., Carides, A., Webb, T., & Schmoll, H.-J. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-009-0680-9 · Cited by 229
Self-citationHesketh, P. J., Rossi, G., Rizzi, G., Palmas, M., Alyasova, A., Bondarenko, I., Lisyanskaya, A., & Gralla, R. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu110 · Cited by 227
Self-citationGrunberg, S., Chua, D., Maru, A., Dinis, J., DeVandry, S., Boice, J. A., Hardwick, J. S., Beckford, E., Taylor, A., Carides, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.7859 · Cited by 217
Self-citationJordan, K., Jahn, F., & Aapro, M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv138 · Cited by 202
Self-citationThe Italian Group for Antiemetic Research (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422102 · Cited by 192
Navari, R. M., Nagy, C. K., & Gray, S. E. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-012-1710-6 · Cited by 181
Molassiotis, A., Aapro, M., Dicato, M., Gascon, P., Novoa, S. A., Isambert, N., Burke, T. A., Gu, A., & Roila, F. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.06.012 · Cited by 158
Self-citationAnticipatory nausea and vomiting due to chemotherapy
Kamen, C. S., Tejani, M. A., Chandwani, K. D., Janelsins, M. C., Peoples, A. R., Roscoe, J. A., & Morrow, G. R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.071 · Cited by 155
Self-citationSchwartzberg, L. S., Modiano, M., Rapoport, B. L., Chasen, M. R., Gridelli, C., Urban, L., Poma, A., Arora, S., Navari, R. M., & Schnadig, I. D. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00034-0 · Cited by 151
Self-citationRapoport, B. L., Chasen, M. R., Gridelli, C., Urban, L., Modiano, M., Schnadig, I. D., Poma, A., Arora, S., Kansra, V. V., Schwartzberg, L. S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00035-2 · Cited by 138
Self-citationBruera, E. D., Belzile, M., Neumann, C. M., Harsanyi, Z., Babul, N., & Darke, A. C. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00138-x · Cited by 123
Self-citationMolassiotis, A., Saunders, M. P., Valle, J. W., Wilson, G., Lorigan, P. C., Wardley, A. M., Levine, E. L., Cowan, R. A., Loncaster, J. A., & Rittenberg, C. N. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-007-0343-7 · Cited by 117
Self-citationAlbany, C., Brames, M. J., Fausel, C. A., Johnson, C. S., Picus, J., & Einhorn, L. H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5558 · Cited by 108
Self-citationDupuis, L. L., Robinson, P. D., Boodhan, S., Holdsworth, M. T., Portwine, C., Gibson, P. J., Phillips, R., Maan, C., Stefin, N., & Sung, L. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25063 · Cited by 94
Self-citationSchmitt, T., Goldschmidt, H., Neben, K., Freiberger, A., Hüsing, J., Gronkowski, M., Thalheimer, M., Pelzl, L. H., Mikus, G., Burhenne, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0095 · Cited by 94
on behalf of the Sancuso Study Group, Boccia, R. V., Gordan, L., Clark, G., Howell, J. D., & Grunberg, S. M. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0990-y · Cited by 84
Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
Currow, D., Quinn, S., Agar, M., Fazekas, B., Hardy, J., McCaffrey, N., Eckermann, S., Abernethy, A., & Clark, K. (2015) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2014.09.013 · Cited by 84
Molassiotis, A., Lee, P. H., Burke, T. A., Dicato, M. A., Gascón, P., Roila, F., & Aapro, M. (2016) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2015.12.317 · Cited by 79
Self-citationAbé, M., Hirashima, Y., Kasamatsu, Y., Kado, N., Komeda, S., Kuji, S., Tanaka, A., Takahashi, N., Takekuma, M., Hihara, H., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2829-z · Cited by 78
Roila, F., Ruggeri, B., Ballatori, E., Favero, A. D., & Tonato, M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4547 · Cited by 76
Self-citationLaugsand, E. A., Kaasa, S., & Klepstad, P. (2011) · Palliative Medicine · doi:10.1177/0269216311404273 · Cited by 72
Radiation-induced emesis: a prospective observational multicenter Italian trial
Maranzano, E., Latini, P., Roila, F., Angelis, V. D., Tonato, M., Ballatori, E., Favero, A. D., Ciccarese, G., Palladino, M., Galardi, A., et al. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00055-3 · Cited by 72
Self-citationEnblom, A., Axelsson, B. B., Steineck, G., Hammar, M. L., & Börjeson, S. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0445-x · Cited by 70
Ito, Y., Karayama, M., Inui, N., Kuroishi, S., Nakano, H., Nakamura, Y., Yokomura, K., Toyoshima, M., Shirai, T., Masuda, M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.017 · Cited by 69
Bruera, E. D., MacEachern, T., Spachynski, K., LeGatt, D. F., MacDonald, R. N., Babul, N., Harsanyi, Z., & Darke, A. C. (1994) · Cancer · Cited by 66
Self-citationMariani, P., Blumberg, J., Landau, A., Lebrun, D., Botton, E., Béatrix, O., Mayeur, D., Hervé, R., Maisonobe, P., & Chauvenet, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5712 · Cited by 58
Salvo, N., Doble, B., Khan, L., Amirthevasar, G., Dennis, K. E. B., Pasetka, M., DeAngelis, C., Tsao, M. N., & Chow, E. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.060 · Cited by 53
Peng, X., Wang, P., Li, S., Zhang, G., & Hu, S. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0455-3 · Cited by 53
Inoue, A., Yamada, Y., Matsumura, Y., Shimada, Y., Muro, K., Gotoh, M., Hamaguchi, T., Mizuno, T., & Shirao, K. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-003-0488-y · Cited by 50
Is delayed chemotherapy-induced emesis well managed in oncological clinical practice?
Fabi, A., Barduagni, M., Lauro, S. D., Portalone, L., Mauri, M., de Marinis, F., Narduzzi, C., Tonini, G., Giampaolo, M., Pacetti, U., et al. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0427-3 · Cited by 49
Ruhlmann, C. H. B., Christensen, T. B., Dohn, L. H., Paludan, M., Rønnengart, E., Halekoh, U., Hilpert, F., Feyer, P., Kristensen, G. B., Hansen, O., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00615-4 · Cited by 48
Self-citationVan Laere, K., De Hoon, J., Bormans, G., Koole, M., Derdelinckx, I., De Lepeleire, I., Declercq, R., Sanabria Bohorquez, S. M., Hamill, T., Mozley, P. D., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.62 · Cited by 46
Hu, Z., Cheng, Y., Zhang, H., Zhou, C., Han, B., Zhang, Y., Huang, C., Chang, J., Song, X., Liang, J., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-2043-9 · Cited by 44
Chan, A., Kim, H.-K., Hsieh, R. K., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2375-0 · Cited by 42
Nausea and Vomiting in Advanced Cancer- “The Cleveland Clinic Protocol”
Gupta, M., Davis, M. P., LeGrand, S. B., Walsh, D., & Lagman, R. L. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.10.002 · Cited by 40
Self-citationHesketh, P. J., Wright, O., Rosati, G., Russo, M., Levin, J., Lane, S. R., Moiseyenko, V. M., Dubé, P., Валериевич, К. М., & Makhson, A. M. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1235-4 · Cited by 30
Self-citationHesketh, P. J., Bosnjak, S. M., Nikolic, V., & Rapoport, B. L. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1286-6 · Cited by 14
Self-citationNavari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., Dietrich, L. L., Lafky, J. M., & Loprinzi, C. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.29_suppl.176 · Cited by 12
Research works printed but not linked: 27
- Grunberg, 2005, Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update, Support Care Cancer, 13, 80, 10.1007/s00520-004-0718-y · doi:10.1007/s00520-004-0718-y
- Saito, 2013, Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial, Ann Oncol, 24, 1067, 10.1093/annonc/mds541 · doi:10.1093/annonc/mds541
- Rapoport, 2015, Study of rolapitant, a novel, long-acting, NK1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC), Support Care Cancer, 23, 3281, 10.1007/s00520-015-2738-1 · doi:10.1007/s00520-015-2738-1
- Roila, 2015, Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study, Ann Oncol, 26, 1248, 10.1093/annonc/mdv132 · doi:10.1093/annonc/mdv132
- Saito, 2009, Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial, Lancet Oncol, 10, 115, 10.1016/S1470-2045(08)70313-9 · doi:10.1016/s1470-2045(08)70313-9
- Brygger, 2014, 5-hydroxytryptamine3 receptor antagonists and cardiac side effects, Expert Opin Drug Saf, 13, 1407, 10.1517/14740338.2014.954546 · DOI
- Karthaus, 2015, Support Care Cancer, 23, 2917, 10.1007/s00520-015-2657-1 · doi:10.1007/s00520-015-2657-1
- Boccia, 2013, Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial, Support Care Cancer, 21, 1453, 10.1007/s00520-012-1691-5 · doi:10.1007/s00520-012-1691-5
- Popovic, 2014, Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials, Support Care Cancer, 22, 1685, 10.1007/s00520-014-2175-6 · doi:10.1007/s00520-014-2175-6
- Weinstein, 2016, Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial, Ann Oncol, 27, 172, 10.1093/annonc/mdv482 · doi:10.1093/annonc/mdv482
- Hesketh, 2016, Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy, Cancer, 122, 2418, 10.1002/cncr.30054 · doi:10.1002/cncr.30054
- Tanioka, 2013, A randomized, placebo controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy, Br J Cancer, 109, 859, 10.1038/bjc.2013.400 · doi:10.1038/bjc.2013.400
- Yahata, 2016, Int J Clin Oncol, 21, 491, 10.1007/s10147-015-0928-y · doi:10.1007/s10147-015-0928-y
- Nishimura, 2015, Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial, Eur J Cancer, 51, 1274, 10.1016/j.ejca.2015.03.024 · DOI
- Olver, 2013, Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in a 5-day cisplatin-based germ cell tumor chemotherapy, Support Care Cancer, 21, 1561, 10.1007/s00520-012-1696-0 · doi:10.1007/s00520-012-1696-0
- Hamada, 2014, Antiemetic efficacy and safety of a combination of palonosetron, aprepitant and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy, Support Care Cancer, 22, 2161, 10.1007/s00520-014-2182-7 · doi:10.1007/s00520-014-2182-7
- Keat, 2013, Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low-emetogenic chemotherapy?, Asian Pac J Cancer Prev, 14, 469, 10.7314/APJCP.2013.14.1.469 · doi:10.7314/apjcp.2013.14.1.469
- Chanthawong, 2014, Effective of olanzapine for the treatment of breakthrough chemotherapy-induced nausea and vomiting, J Med Assoc Thai, 97, 349
- Sigsgaard, 2001, Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy, J Clin Oncol, 19, 2091, 10.1200/JCO.2001.19.7.2091 · doi:10.1200/jco.2001.19.7.2091
- Pielichowski, 2011, A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation, Transplant Proc, 43, 3107, 10.1016/j.transproceed.2011.08.010 · doi:10.1016/j.transproceed.2011.08.010
- Bechtel, 2014, Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study, Support Care Cancer, 22, 2911, 10.1007/s00520-014-2248-6 · doi:10.1007/s00520-014-2248-6
- Stiff, 2013, Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens, Biol Blood Marrow Transplant, 19, 49, 10.1016/j.bbmt.2012.07.019 · doi:10.1016/j.bbmt.2012.07.019
- Maranzano, 2010, A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres, Radiother Oncol, 94, 36, 10.1016/j.radonc.2009.11.001 · doi:10.1016/j.radonc.2009.11.001
- Dennis, 2013, Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies, J Radiat Oncol, 2, 271, 10.1007/s13566-012-0030-2 · doi:10.1007/s13566-012-0030-2
- Bakhshi, 2015, Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial, Support Care Cancer, 23, 3229, 10.1007/s00520-015-2714-9 · DOI
- Kang, 2015, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial, Lancet Oncol, 16, 385, 10.1016/S1470-2045(15)70061-6 · doi:10.1016/s1470-2045(15)70061-6
- Laval, 2012, SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction, Bull Cancer, 99, E1, 10.1684/bdc.2011.1535 · doi:10.1684/bdc.2011.1535
Cited by
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationBiganzoli, L., Battisti, N. M. L., Wildiers, H., McCartney, A., Colloca, G., Kunkler, I. H., Cardoso, M.-J., Cheung, K.-L., de Glas, N. A., Trimboli, R. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30741-5 · Cited by 298
Self-citationMechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
Metadata
- Authors
- Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., Clark-Snow, R. A., Dupuis, L. L., Einhorn, L. H., Feyer, P., Hesketh, P. J., Jordan, K., Olver, I., Rapoport, B. L., Roscoe, J., Ruhlmann, C. H., Walsh, D., Warr, D., & van der Wetering, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Issue
- suppl 5
- Pages
- v119-v133
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2527377692
- Cited by
- 574
- References
- 41
- FWCI
- 62.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1209 d)
- Funders
- MASCC
- ESMO
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.